Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma - Wikidata - wikimedia - TriplyDB

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

http://www.wikidata.org/entity/Q34593345

about

Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma Systemic therapy of hepatocellular carcinoma: current status and future perspectives Targeted therapy for hepatocellular carcinoma: novel agents on the horizon Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action Nanomedicine strategies for sustained, controlled, and targeted treatment of cancer stem cells of the digestive system Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.Effects of miR-193a and sorafenib on hepatocellular carcinoma cells.Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF-A expression in hepatocellular carcinoma.Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults.Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply.Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies.Therapeutic effect of a TM4SF5-specific monoclonal antibody against colon cancer in a mouse model.Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials.Updates in the management of hepatocellular carcinoma Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields.Liver cancer: Targeted future options V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials.Simultaneous silencing of VEGF and KSP by siRNA cocktail inhibits proliferation and induces apoptosis of hepatocellular carcinoma Hep3B cells.Novel therapeutic strategies for targeting liver cancer stem cells.Targeting metastatic upper gastrointestinal adenocarcinomas Hep88 mAb-initiated paraptosis-like PCD pathway in hepatocellular carcinoma cell line through the binding of mortalin (HSPA9) and alpha-enolase.Targeted therapy in hepatocellular carcinoma Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview.Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.HCC and angiogenesis: possible targets and future directions Mixed response and time-to-event endpoints for multistage single-arm phase II design

P2860

Q26823523-39D1E54A-7D4C-4AF1-B989-25597A2C9997 Q26865844-E69E34C3-83BB-4D4F-A510-617FD69D02BF Q27002288-1AE18007-D52C-402C-A0D6-6153F6E91FEF Q27005850-BD07BD58-2E6B-4591-9663-A63E65C4C0FC Q27693179-BBF1F85A-F25B-4070-8243-6C64E7F9B80F Q28079367-D2F29773-763D-40E3-B361-BCCBE1F8A3E7 Q30479629-96779E97-248B-488F-AEB7-860B19FE73C8 Q33382481-08C407F6-C790-4E8E-BD59-596D92F9A526 Q33644158-D340FDF9-88EC-4D60-BF96-F9C6A1C0A787 Q33695543-26312BCA-7D28-4150-981D-BF0EA70FA02F Q33747394-5E1A92EF-3601-4FE3-97F4-FDF2A980E185 Q33798661-90467996-DC21-45EE-8B90-97D0DFBC1519 Q33807542-51C68EAE-E172-4798-A577-1B42D13C97D6 Q33847973-9E7FA87A-3F45-4D64-9E0B-6B63B122C76D Q33920350-CEA1A2A0-927D-4394-AE25-3157F4F1543A Q34131801-E7234C92-CD11-4735-B43E-32659BBF8B23 Q34253748-5E1C7D31-8E3B-4BB4-8215-0B82ED771453 Q34309960-63EA8EA2-1753-4E99-88B3-E7E7F62CD598 Q34358256-C2311271-35B3-4190-8F23-3094CF387A95 Q34402650-7338C113-E120-4F7E-B564-84909F5ED296 Q34409128-CA963CAB-DEA4-43E2-84AC-D0A6703A3AD1 Q34483608-EA694249-7C57-4CA9-AEB8-0AEA9A6399BC Q34504649-C53C77AE-1227-4DDE-B2CE-556E0CE38E81 Q34531474-ED335FD1-0FE2-463F-BEEE-D97A17AAD10D Q34571160-FD0D5C53-D7B2-46C9-BEE0-F4A5528298C7 Q34617414-DD1595A0-227F-41ED-9604-78E43BF9E929 Q34631518-3CE98FE3-8435-4238-94B0-AA16515270C6 Q34695180-1DD80207-9D1A-4CDD-80A2-82852835498F Q34733478-D9F2A0C0-C5DC-4CDE-9E26-BB3AEED627AE Q34900837-BAEEE441-DD1C-422B-B430-1CA54DDCAB48 Q34940971-5DE86B0D-BBA8-400B-BD7E-878C99F1A861 Q35000785-1F3971ED-CD41-4C0A-8D7C-D39B06BB55AF Q35189366-E0B938EB-5F4E-4650-8863-52BE02F491FF Q35207561-E2E9C0B5-AB34-4305-B02E-A082B6FBBA03 Q35230282-90772E4A-00AA-48A1-A8FD-FE21B9ADFEDB Q35541482-5B571656-95DC-426A-A8F0-977A695ECEA5 Q35640101-FE11AD63-78FD-434A-B046-8CAF238968C3 Q35670736-38F490F2-E0CA-4975-8CAD-0BEC595C9A7B Q35698574-74B81C67-140D-4CAC-A308-51BCF584A084 Q35700578-4B04CFE8-1BFB-4017-AFDA-2B41E1D222C0

P2860

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

http://www.wikidata.org/entity/Q34593345

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Phase II trial evaluating the ...... table hepatocellular carcinoma

@ast

Phase II trial evaluating the ...... table hepatocellular carcinoma

@en

Phase II trial evaluating the ...... table hepatocellular carcinoma

@nl

type

label

Phase II trial evaluating the ...... table hepatocellular carcinoma

@ast

Phase II trial evaluating the ...... table hepatocellular carcinoma

@en

Phase II trial evaluating the ...... table hepatocellular carcinoma

@nl

prefLabel

Phase II trial evaluating the ...... table hepatocellular carcinoma

@ast

Phase II trial evaluating the ...... table hepatocellular carcinoma

@en

Phase II trial evaluating the ...... table hepatocellular carcinoma

@nl

P1433

Q34593345-E7F5734A-9E85-4063-BDBC-362279F1C0F1

P1476

Q34593345-C092AB93-F3CC-485C-84F5-0E967A2C2C86

P2093

Q34593345-00DD83DB-8732-430F-8CA8-23CFF5F3F0D2

Q34593345-04A56095-E75D-4776-B3B3-E92E6A53B3EC

Q34593345-0F3A20BB-8D0E-4AF4-9395-E1712EB7F499

Q34593345-2C8A0C5A-75FD-448B-8EEF-DED9679772E1

Q34593345-2E0927A4-977F-4D0C-B0FA-5C356B669D79

Q34593345-35B7F963-24C1-45B4-837E-617EA3804CE9

Q34593345-3DBD920E-C663-43F7-9AFF-A507CDAB56CB

Q34593345-44B115F8-837A-4E80-A632-F344D622F834

Q34593345-44B197B3-9ACC-459C-9A6C-F12EE9F227C5

Q34593345-469ED86E-4DC2-4C5A-B91F-AE09E6F3736D

P2860

Q34593345-01B4C2B3-A4BC-4D83-B8CA-D08C68EA64D9

Q34593345-158DE8AC-8127-47D8-BFFA-20BBD33D94E6

Q34593345-27C8025B-BBC9-4D29-8F8E-DB42953B3842

Q34593345-4181634F-860C-457B-95BD-4C0C318A8360

Q34593345-5EE3ED4B-E20A-4FD5-B8DF-77B9C00A786B

Q34593345-7EA55C42-C567-4E2C-A3CD-2B43398A9197

Q34593345-814B67FB-5218-4B02-89C1-AEE542D82C37

Q34593345-907B408F-C5C9-4B15-865D-FFF7344E1676

Q34593345-9363BD4E-3A44-47FF-B078-C72521BAB368

Q34593345-A1D4EE2E-37A3-433B-9B1C-4A5776877C81

P304

Q34593345-1C122967-08B7-4A00-9245-1BCFBA2D3F4F

P31

Q34593345-E4674B30-8B2C-4229-B89F-6D49F6B4D3F6

P356

Q34593345-20954B5F-C77B-44F4-856B-CF8BA2FE601F

P407

Q34593345-1BC9DA1D-3EE2-4716-8881-797CA56CB4FD

P433

Q34593345-54F08CB4-F9E2-4001-9E8D-E4097A127863

P478

Q34593345-A499C31F-2BEF-4333-9E36-7FE9E9454187

P577

Q34593345-70D2147B-D4CD-490A-8690-42BD37DC12F2

P698

Q34593345-B911AAAA-49F5-4DCE-8ABC-1559CDB9CC9A

P921

Q34593345-29E9A9DD-CD0B-4374-AFA2-888786B3A52C

Q34593345-A8D1C33C-6497-4A5A-8E0D-56C6E661B1C6

P932

Q34593345-B76C2AC7-A797-4C7E-93B2-5EDA02BC098B

P356

JCO.2007.15.9947

P1433

Journal of Clinical Oncology

P1476

Phase II trial evaluating the ...... table hepatocellular carcinoma

@en

P2093

Abby B Siegel

http://www.w3.org/2001/XMLSchema#string

Alan Weinberg

http://www.w3.org/2001/XMLSchema#string

Alec Goldenberg

http://www.w3.org/2001/XMLSchema#string

Allyson Ocean

http://www.w3.org/2001/XMLSchema#string

Deborah Lehrer

http://www.w3.org/2001/XMLSchema#string

Elizabeta Popa

http://www.w3.org/2001/XMLSchema#string

Emil I Cohen

http://www.w3.org/2001/XMLSchema#string

Helen Chen

http://www.w3.org/2001/XMLSchema#string

Jennifer J Knox

http://www.w3.org/2001/XMLSchema#string

John Mandeli

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.

Quantitative analysis of focal masses at MR imaging: a plea for standardization.

Angiogenesis and hepatocellular carcinoma.

Opportunities for targeted therapies in hepatocellular carcinoma.

Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression.

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.

P304

2992-2998

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.15.9947

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18565886

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3635806

http://www.w3.org/2001/XMLSchema#string